Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--